CompletedPhase 2NCT04322149
Multiple Doses of AT-1501-A201 in Adults With ALS
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anelixis Therapeutics, LLC
- Principal Investigator
- Jeff Bornstein, MDEledon Pharmaceuticals
- Intervention
- AT-1501(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (13)
- Barrows Neurological Institute, Phoenix, Arizona, United States
- University of California Irvine, Orange, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- Augusta University, Augusta, Georgia, United States
- University of Indiana, Indianapolis, Indiana, United States
- The University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins University Medical Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Hospital for Special Surgery (HSS), New York, New York, United States
- Providence Brain & Spine Institute, Portland, Oregon, United States
- Texas Neurology, P.A., Dallas, Texas, United States
- Houston Methodist Neurological Institute, Houston, Texas, United States
- Montreal Neurological Institute and Hospital, Montreal, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04322149 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)